Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Nguyen, HG; Tilki, D; Dall'Era, MA; Durbin-Johnson, B; Carballido, JA; Chandrasekar, T; Chromecki, T; Ciancio, G; Daneshmand, S; Gontero, P; Gonzalez, J; Haferkamp, A; Hohenfellner, M; Huang, WC; Espinós, EL; Mandel, P; Martinez-Salamanca, JI; Master, VA; McKiernan, JM; Montorsi, F; Novara, G; Pahernik, S; Palou, J; Pruthi, RS; Rodriguez-Faba, O; Russo, P; Scherr, DS; Shariat, SF; Spahn, M; Terrone, C; Vergho, D; Wallen, EM; Xylinas, E; Zigeuner, R; Libertino, JA; Evans, CP.
Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis.
J Urol. 2015; 194(2):304-308
Doi: 10.1016/j.juro.2015.02.2948
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Chromecki Thomas
- Zigeuner Richard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The impact of cardiopulmonary bypass in level III-IV tumor thrombectomy on surgical and oncologic outcomes is unknown. We determine the impact of cardiopulmonary bypass on overall and cancer specific survival, as well as surgical complication rates and immediate outcomes in patients undergoing nephrectomy and level III-IV tumor thrombectomy with or without cardiopulmonary bypass. We retrospectively analyzed 362 patients with renal cell cancer and with level III or IV tumor thrombus from 1992 to 2012 at 22 U.S. and European centers. Cox proportional hazards models were used to compare overall and cancer specific survival between patients with and without cardiopulmonary bypass. Perioperative mortality and complication rates were assessed using logistic regression analyses. Median overall survival was 24.6 months in noncardiopulmonary bypass cases and 26.6 months in cardiopulmonary bypass cases. Overall survival and cancer specific survival did not differ significantly in both groups on univariate analysis or when adjusting for known risk factors. On multivariate analysis no significant differences were seen in hospital length of stay, Clavien 1-4 complication rate, intraoperative or 30-day mortality and cancer specific survival. Limitations include the retrospective nature of the study. In our multi-institutional analysis the use of cardiopulmonary bypass did not significantly impact cancer specific survival or overall survival in patients undergoing nephrectomy and level III or IV tumor thrombectomy. Neither approach was independently associated with increased mortality on multivariate analysis. Greater surgical complications were not independently associated with the use of cardiopulmonary bypass. Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Carcinoma, Renal Cell - mortality
- Carcinoma, Renal Cell - pathology
- Carcinoma, Renal Cell - surgery
- Cardiopulmonary Bypass -
- Female -
- Humans -
- Kidney Neoplasms - mortality
- Kidney Neoplasms - pathology
- Kidney Neoplasms - surgery
- Male -
- Middle Aged -
- Neoplastic Cells, Circulating -
- Nephrectomy - methods
- Retrospective Studies -
- Survival Rate - trends
- Thrombectomy - methods
- Thrombectomy - epidemiology
- Vena Cava, Inferior -
- Venous Thrombosis - etiology
- Venous Thrombosis - mortality
- Venous Thrombosis - surgery
- Find related publications in this database (Keywords)
- carcinoma, renal cell
- cardiopulmonary bypass
- vena cava, inferior
- survival
- intraoperative complications